Targeting miR-155 to Treat Experimental Scleroderma.

Area of Science:

• Dermatology
• Molecular Biology
• Immunology

Background:

• Scleroderma is a challenging autoimmune fibrotic skin disease.
• MicroRNAs (miRNAs) are implicated in fibrotic disorders.
• Altering miRNA expression presents a potential therapeutic strategy for scleroderma.

Purpose of the Study:

• To investigate the role of miR-155 in scleroderma pathogenesis.
• To evaluate miR-155 as a therapeutic target for dermal fibrosis.
• To explore the mechanisms underlying miR-155's pro-fibrotic effects.

Main Methods:

• Analysis of miR-155 expression in patient skin biopsies.
• Utilizing miR-155 knockout mice and bleomycin-induced fibrosis models.
• Investigating the effects of miR-155 silencing on fibroblast collagen synthesis.
• Assessing the impact on Wnt/β-catenin and Akt signaling pathways.

Main Results:

• miR-155 expression is upregulated in scleroderma lesional skin and correlates with fibrosis.
• miR-155 knockout mice exhibit resistance to bleomycin-induced skin fibrosis.
• Topical antagomir-155 treatment ameliorates fibrosis in a preclinical model.
• miR-155 silencing inhibits collagen synthesis and pro-fibrotic signaling pathways (Wnt/β-catenin, Akt) in fibroblasts.
• miR-155 directly targets CK1α and SHIP-1, regulating these pathways.

Conclusions:

• miR-155 is a key driver of dermal fibrosis in scleroderma.
• Targeting miR-155, especially via topical application, is a promising therapeutic strategy for scleroderma.
• Inhibition of miR-155 effectively reduces fibrosis by modulating key pro-fibrotic signaling pathways.